Graves' disease, rheumatoid arthritis, and anti-tumor necrosis factor-alpha therapy. 2009

Jae Il Shin, and Min Jung Kim, and Jae Seung Lee

UI MeSH Term Description Entries
D007049 Iatrogenic Disease Any adverse condition in a patient occurring as the result of treatment by a physician, surgeon, or other health professional, especially infections acquired by a patient during the course of treatment. Hospital-Acquired Condition,Condition, Hospital-Acquired,Conditions, Hospital-Acquired,Disease, Iatrogenic,Diseases, Iatrogenic,Hospital Acquired Condition,Hospital-Acquired Conditions,Iatrogenic Diseases
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008991 Monitoring, Physiologic The continuous measurement of physiological processes, blood pressure, heart rate, renal output, reflexes, respiration, etc., in a patient or experimental animal; includes pharmacologic monitoring, the measurement of administered drugs or their metabolites in the blood, tissues, or urine. Patient Monitoring,Monitoring, Physiological,Physiologic Monitoring,Monitoring, Patient,Physiological Monitoring
D003429 Cross Reactions Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen. Cross Reaction,Reaction, Cross,Reactions, Cross
D005260 Female Females
D006111 Graves Disease A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy). Basedow's Disease,Exophthalmic Goiter,Goiter, Exophthalmic,Graves' Disease,Basedow Disease,Hyperthyroidism, Autoimmune,Basedows Disease,Disease, Basedow,Disease, Basedow's,Disease, Graves,Disease, Graves',Exophthalmic Goiters,Goiters, Exophthalmic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068800 Etanercept A recombinant version of soluble human TNF receptor fused to an IgG FC fragment that binds specifically to TUMOR NECROSIS FACTOR and inhibits its binding with endogenous TNF receptors. It prevents the inflammatory effect of TNF and is used to treat RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS and ANKYLOSING SPONDYLITIS. Enbrel,Erelzi,Etanercept-szzs,Recombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,TNF Receptor Type II-IgG Fusion Protein,TNFR-Fc Fusion Protein,TNR 001,TNR-001,TNT Receptor Fusion Protein,TNTR-Fc,Fusion Protein, TNFR-Fc,Recombinant Human Dimeric TNF Receptor Type II IgG Fusion Protein,TNF Receptor Type II IgG Fusion Protein,TNFR Fc Fusion Protein,TNR001
D000068879 Adalimumab A humanized monoclonal antibody that binds specifically to TNF-ALPHA and blocks its interaction with endogenous TNF RECEPTORS to modulate INFLAMMATION. It is used in the treatment of RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS; CROHN'S DISEASE and ULCERATIVE COLITIS. Adalimumab-adbm,Adalimumab-atto,Amjevita,Cyltezo,D2E7 Antibody,Humira,Antibody, D2E7

Related Publications

Jae Il Shin, and Min Jung Kim, and Jae Seung Lee
January 1997, Advances in immunology,
Jae Il Shin, and Min Jung Kim, and Jae Seung Lee
May 2008, The Journal of rheumatology,
Jae Il Shin, and Min Jung Kim, and Jae Seung Lee
August 1998, Rheumatic diseases clinics of North America,
Jae Il Shin, and Min Jung Kim, and Jae Seung Lee
September 1997, European cytokine network,
Jae Il Shin, and Min Jung Kim, and Jae Seung Lee
October 1999, Issues in emerging health technologies,
Jae Il Shin, and Min Jung Kim, and Jae Seung Lee
January 2001, Autoimmunity,
Jae Il Shin, and Min Jung Kim, and Jae Seung Lee
July 2007, The Journal of rheumatology,
Jae Il Shin, and Min Jung Kim, and Jae Seung Lee
September 2009, Journal of periodontology,
Jae Il Shin, and Min Jung Kim, and Jae Seung Lee
April 2004, Arthritis and rheumatism,
Copied contents to your clipboard!